These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 30646152)

  • 1. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels.
    Pandya A; Asch DA; Volpp KG; Sy S; Troxel AB; Zhu J; Weinstein MC; Rosenthal MB; Gaziano TA
    JAMA Netw Open; 2018 Sep; 1(5):e182008. PubMed ID: 30646152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.
    Asch DA; Troxel AB; Stewart WF; Sequist TD; Jones JB; Hirsch AG; Hoffer K; Zhu J; Wang W; Hodlofski A; Frasch AB; Weiner MG; Finnerty DD; Rosenthal MB; Gangemi K; Volpp KG
    JAMA; 2015 Nov; 314(18):1926-35. PubMed ID: 26547464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
    Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
    PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
    Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
    PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial.
    Barankay I; Reese PP; Putt ME; Russell LB; Loewenstein G; Pagnotti D; Yan J; Zhu J; McGilloway R; Brennan T; Finnerty D; Hoffer K; Chadha S; Volpp KG
    JAMA Netw Open; 2020 Oct; 3(10):e2019429. PubMed ID: 33034639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement.
    Smith KC; Paltiel AD; Yang HY; Collins JE; Katz JN; Losina E
    Osteoarthritis Cartilage; 2018 Nov; 26(11):1495-1505. PubMed ID: 30092263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina.
    Zhang Y; Yin L; Mills K; Chen J; He J; Palacios A; Riviere AP; Irazola V; Augustovski F; Shi L
    JAMA Netw Open; 2021 Sep; 4(9):e2122559. PubMed ID: 34519769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.
    Kohli-Lynch CN; Bellows BK; Zhang Y; Spring B; Kazi DS; Pletcher MJ; Vittinghoff E; Allen NB; Moran AE
    J Am Coll Cardiol; 2021 Nov; 78(20):1954-1964. PubMed ID: 34763772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are financial incentives cost-effective to support smoking cessation during pregnancy?
    Boyd KA; Briggs AH; Bauld L; Sinclair L; Tappin D
    Addiction; 2016 Feb; 111(2):360-70. PubMed ID: 26370095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.